2016 Fall Symposium

Uri Tabori, MD
The Yin and Yang of Cancer Genetics: Pediatric Cancer Predisposition in the Genomics Era

Uri Tabori, MD

Learning Outcomes:
  • Define recent findings of cancer germline predisposition in pediatric brain cancers.
  • Discuss how these discoveries affect cancer patient and family management.
  • Assess the evolution of novel therapies which improve survival in the current era.

Dr Tabori is a Haematology/Oncology clinician scientist at the University of Toronto Hospital for Sick Children, associate professor of Pediatrics in the Institute of Medical Sciences, and Senior Scientist in the Genetic and Genomic Biology Research Institute. Dr Tabori’s main areas of interest are translational aspects of 1) telomere biology and self-renewal of pediatric cancers 2) genetic predisposition to pediatric brain tumors and 3) translational aspects for pediatric gliomas. Dr Tabori has developed and patented tools to determine cancer aggressiveness using genetic and epigenetic signatures of telomerase activation. He is also developing novel noninvasive tools to detect cancer in body fluids. Dr. Tabori and his team have recently uncovered the translational implications of the unique ultrahypermutation signature of children affected by germline mutations in mismatch repair genes, resulting in novel therapies for these patients and hypermutant cancers. He has also along with the PLGG taskforce uncovered genetic markers in pediatric low grade gliomas which affect the outcome of these cancers and are amenable to targeted therapies. Dr. Tabori plays leadership roles in several national and international committees, task forces and clinical trials in the International Society of Pediatric Oncology and the Children’s Oncology Group of North America. Dr Tabori is also the founding director of the International Biallelic Mismatch Repair Deficiency Consortium.